Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI-120 vs Neulasta Pharmacokinetics and Pharmacodynamics in Healthy Adults
NCT03206229Phase 1Completed
- Sponsor
- Adello Biologics, LLC
- Start
- Feb 2017
- Primary completion
- Jun 2017
- Modality
- PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pegfilgrastim-apgf in neutropenia (2 arms), sponsored by Adello Biologics, LLC. Primary endpoints: Maximum observed concentration at 56 days, Area under the concentration-time curve from time zero to the time of the last non-zero concentration at 56 days and 3 more. Started Feb 2017; status: completed.
02
Drugs
pegfilgrastim-apgf
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT03206229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03206229.